Latest released the research study by Market Research Future (MRFR) on circulating tumor cell technology market Demand, offers a detailed overview of the factors influencing the global business scope.
Circulating Tumor Cell Market To reach $28,300 million at highest CAGR by 2023. Advancements in biomedical imaging technology and soaring prevalence of cancer to boost growth of Global Circulating Tumor Cell Market. Global Circulating Tumor Cell Market analysis by Application (Research, Drug Development), Technology (CTC Enrichment, CTC Detection), End-User (Hospital & Clinics, Research & Academic Institutes, Diagnostic Centers) — Forecast Till 2023.
The players dominating the global circulating tumor cell market includes Greiner Bio-One International GmbH, Ikonisys Inc., SRI International, Thermo Fisher Scientific, Miltenyi Biotec, STEMCELL Technologies, QIAGEN Hannover (QIAGEN), Menarini Silicon Biosystems, NanoString Technologies, Inc, F. Hoffmann-La Roche Ltd, GE Healthcare, Fluxion Biosciences, Inc., Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation), ApoCell, and Epic Lifesciences, Celltraffix Inc.
Global Circulating Tumor Cell Market Overview
The circulating tumor cell (CTC) market is anticipated to surpass a valuation of USD 28,300 million, attaining a healthy CAGR during the forecast period (2018–2023), Market Research Future (MRFR) reveals in a detailed analysis. Advent of Cluster Chip Technology to Assist in Circulating Tumor Cell Market Growth
The global circulating tumor cell market has gained huge attention over the past few years. The prevalence of CTC has increased in the recent past. The mechanism of CTC is majorly responsible for deaths caused by cancer. Notable progress has been made to develop effective diagnostics and treatment, which encourages the market growth. Healthcare companies are highly focusing on developing solutions, which allow quick and accurate detection of CTC.
The soaring prevalence of cancer is one of the prominent factors predicted to influence the growth of the market in the foreseeable future. Majority of deaths caused by cancer are cancers having metastasized, which leads to the field of circulating tumor cells taking on a crucial position in modern oncology. Advancements made in bioengineering and biomedical imaging technology is considered a prominent factor encouraging the market growth. The role of translation research and genomics in the development of methods, which can improve enumeration, detection, and analysis of CTC in patient specimens is predicted to influence the market growth in the coming years. The surging adoption of companion diagnostic option and personalized medicine for the eradication of cancer from the infection site is likely to boost the market growth in the coming years. Moreover, the rising need for diagnosis, oncology screening, and therapy monitoring to determine patient’s health will elevate the scope for the market in years to come.
The advent of Cluster Chip Technology is considered a major factor driving the market for CTC globally. This technology can be used for the isolation of circulating tumor cells from the bloodstream by using a microfluidic device.
On the contrary, the dearth of awareness, along with the reluctance for the adoption of advanced CTC technologies are some of the concerns likely to restrict the market growth in the foreseeable future.
Global Circulating Tumor Cell Market: Segmental Analysis
The circulating tumor cell market is segmented on the basis of application, technology, and end user.
By application, the circulating tumor cell market is segmented into research, clinical, and drug development.
By technology, the circulating tumor cell market is segmented into CTC detection, CTC enrichment, and combined enrichment and separation of CTC. Of these, the CTC enrichment segment is predicted to gain prominence due to the extensive use of this method as a result of a wide scope of applications in oncology research. The presence of several methods based on electrochemical and physical properties of CTCs for their enrichment also enhances the market growth in the CTC enrichment segment.
By end user, the market comprises research and academic institutes, hospitals and clinics, and diagnostic centers.
Regional Analysis:
Geographically, the circulating tumor cell market spans across South America, North America, Asia Pacific, Europe, and the Middle East & Africa.
Considering the global scenario, North America will dominate the global market and is likely to retain its dominance in the foreseeable future. The highly advanced state of the healthcare industry in the region is considered a key factor conducive for the healthy growth of the market in the region. The soaring incidences of cancer, coupled with the rising efforts to enhance and update the means to combat the disease, are predicted to trigger the demand from the circulating tumor cell market.
The Asia Pacific is predicted to demonstrate a healthy growth in the coming years owing to the soaring healthcare expenditure, especially in emerging economies, coupled with the surging prevalence of cancer among the population. Moreover, international companies are showing interest to expand their business in countries like China and India, which will further encourage the market growth. Also, the presence of untapped opportunities in these economies is predicted to augment the market share.
Browse more information at: https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362
Industry Updates
June 2019: A team of researchers from the University of Arkansas for Medical Sciences has recently developed a non-invasive device which can detect circulating tumor cells as well as blast them away at the same time. This device, Cytophone, can employ a laser which heats the CTCs and detects them with ultrasound before turning up the heat to kill them.
Related Reports
Gastrointestinal Stromal Tumors Market
North America Hearing Aid Market
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Analysis and Insights: Hematology Analyzer Market Hematology Analyzer Market By Product and Services (Hematology Products & Services, Hemostasis Products & Services, Immunohematology Products & Services), Price Range (High-End Hematology Analyzers, Mid-Range Hematology Analyzers, Low-End Hematology Analyzers), End User (Hospital Laboratories, Commercial Service Providers, Government Reference Laboratories, Research and Academic Institutes), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026Global hematology analyzer market estimated to rise at a substantial CAGR of 6.6% in the forecast period of 2019 to 2026.
The growth of the market can be attributed to the rising blood donation awareness among people.Request Sample is Available @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hematology-analyzer-marketMarket Definition: Global Hematology Analyzer MarketHematology analyzers are medical devices used to run tests on blood samples in which counting of WBC is performed by Hematology analyzers.
It also controls the plasma level for drugs.
These analyzers help in number of diseases, such as anemia, infections and cancer among others.Market DriversRising cases of blood disorders is boosting the market growthInnovations in several field including pharmacogenomics, genetic therapies, hemoglobinopathies, stem cell research and proteomics will propel the growth of the marketAdoption of automated hematology instruments amalgamate with rising preferences of high sensitivity hematology testing is also fueling the market in the forecast periodIntegration of hematology analyzers with flow cytometry will act as a driver for the market growthMarket RestraintsSafety alerts and product recalls is hampering the market growthSlow adoption of advanced hematology instruments in emerging countries may hinder the growth of the marketStringent regulatory policies for hematology analyzers will restraint the market in the forecast periodSegmentation: Global Hematology Analyzer MarketBy Product and ServicesHematology Products & ServicesInstrumentsReagents & ConsumablesServicesHemostasis Products & ServicesInstrumentsReagents & ConsumablesServicesImmunohematology Products & ServicesInstrumentsReagents & ConsumablesServicesFor Further Detailed insights and ‘Any Query About this report @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hematology-analyzer-marketBy Price RangeHigh-End Hematology AnalyzersMid-Range Hematology Analyzers Low-End Hematology AnalyzersBy End UserHospital LaboratoriesCommercial Service ProvidersGovernment Reference LaboratoriesResearch and Academic InstitutesBy GeographyNorth AmericaU.S.CanadaMexicoSouth AmericaBrazilRest of South AmericaEuropeGermanyItalyU.K.FranceSpainNetherlandsBelgiumSwitzerlandTurkeyRussiaRest of EuropeAsia-PacificJapanChinaIndiaSouth KoreaAustraliaIndonesiaMalaysiaSingaporeThailandPhilippinesRest of Asia-PacificMiddle East and AfricaSouth AfricaRest of Middle East & AfricaKey Developments in the Market:In November 2018, PixCell Medical Technologies Ltd. got FDA 510(k) clearance for its product PixCellm Medical’s HemoScreen.
The product will help in native-state cellular characterization for early sepsis detection.
This innovation will lead Beckman Coulter advancement in clinical diagnosticsCompetitive Analysis:Global hematology analyzer market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market.
Global transgenic animals market research report: by products (gene gun, microinjection), techniques (DNA microinjection), consumables (probes), application (monoclonal Abs), transgenic animals (mice) end user (biotech industries) – Forecast till 2027Transgenic animals have a deliberately altered genetic make-up and are extensively exploited in the veterinary, medical sciences, and research sectors.
The Americas leads the global transgenic animals market due to increasing prevalence of diabetes and cardiovascular disorders, growing biotechnology sector, and rising acceptance of transgenic products.
However, high cost and stringent FDA approval policies may restrain the market growth within the region.Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5464On the regional basis, the Americas transgenic animals market is segmented into the two major regions, i.e., North America and South America.
North America dominates the Americas transgenic animals market due to the presence of developed economies like the U.S. and Canada within the region.
However, the South America segment is showing the fastest growth in the market due to the presence of huge opportunities for the development of the market.The Americas transgenic animals market is segmented on the basis of product, techniques, consumables, application, model organism, and end-user.On the basis of the product, the market is categorized into PCR, gene gun, microinjections, electroporator, and others.
The PCR segment is sub segmented into real time PCR, digital PCR systems, and others.
Factors such as the rising government funding and growth in the number of genomics projects, decreasing sequencing costs, growing application areas of genomics, and the entry of new players and start-ups in the genomics field are driving the growth of the genomics market during the forecast period.The report Genomics Market is projected to reach USD 35.7 billion by 2024 from USD 18.9 billion in 2019, at a CAGR of 13.5% during the forecast period.Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=613Market Segmentation:- Based on product & service, the genomics market is segmented into consumables, systems & software, and services.
In 2018, the consumables segment accounted for the largest share of this market majorly due to the repeated use of consumables for genomic experiments and the increasing number of research programs by academic institutes and non-profit organizations.By technology, the genomics market is segmented into sequencing, microarray, PCR (polymerase chain reaction), nucleic acid extraction and purification, and other technologies (such as branched DNA analysis, single-cell genomic analysis, and flow cytometry).Based on application, the genomics market is segmented into diagnostics, drug discovery and development, personalized medicine, agriculture and animal research, and other applications (such as forensics and biofuel research).Market Drivers: – 1 Rising Government Funding and Growth in the Number of Genomics Projects 2 Decreasing Sequencing Costs 3 Growing Application Areas of Genomics 4 Entry of New Players and Start-Ups in the Genomics MarketRegional Analysis:-In 2018, North America was the largest regional market for genomics.
The large share of North America in the global genomics market can be attributed to the increasing research funding and government initiatives for promoting precision medicine and the use of GM crops in the US.
The Asia Pacific market, on the other hand, is expected to register the highest CAGR during the forecast period.Speak To Analyst:- https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=613Top key Players:-Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), BGI (China), GE Healthcare (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and Oxford Nanopore Technologies (UK) are the key players operating in the genomics market.
There are two forms of in-situ hybridization, namely chromogenic in-situ hybridization (CISH) and fluorescence in-situ hybridization (FISH) which are used to classify the role of genes that provide useful insights into tumors.In-situ hybridization is a powerful technique for distinguishing between different mRNA species within individual cells in tissue parts, providing insight into physiological processes and disease pathogenesis.
The growing scenario of cancer has also encouraged government agencies to build and invest in innovative testing alternatives.The National Cancer Institute estimates that the U.S. government spending on cancer care was nearly USD 125 billion in 2010 and is projected to reach USD 156 billion in 2020.This in-situ hybridization devices market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.
Such categories allow you to evaluate progress in different niche exchanges and consumer strategy approaches and define the main areas of operation, as well as help you uncover the main difference between your target markets.Know More About this Report @ https://www.databridgemarketresearch.com/reports/north-america-in-situ-hybridization-devices-market Based on the technology, North America in-situ hybridization devices market is mainly segmented into fluorescence in-situ hybridization (FISH) and chromogenic in-situ hybridization (CISH).Based on the probe type, North America in-situ hybridization devices market is segmented into two categories DNA and RNA.Based on the device, North America in-situ hybridization devices market is divided into three notable segments that are instruments, consumables & accessories, services and software.
Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.Healthcare Infrastructure Growth Installed Base and New Technology PenetrationNorth America in-situ hybridization devices market report also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for North America in-situ hybridization devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the North America in-situ hybridization devices market.
Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance.
The above data points provided are only related to the companies’ focus related to in-situ hybridization devices market.The major players of North America in-situ hybridization devices market covered in the report are Abbott, F. Hoffmann-La Roche Ltd, BioGenex, Merck KGaA, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer Inc., Danaher, Sysmex Corporation, Bio-Techne, Advanced Cell Diagnostics, Inc., Bio SB, Oxford Gene Technology, LGC Biosearch Technologies, Genemed Biotechnologies, Inc., Bio-Rad Laboratories, Inc., NeoGenomics Laboratories, Inc. among other regional and domestic players.In July 2019, Bio-Techne announced the extension of the Advanced Cell Diagnostics RNAscope program with the launch of the HiPlex Assay RNAscope.
Market HighlightsThe global seasonal affective disorder market is growing moderately, and it is expected to grow at the same pace over the forecast period 2017-2018.
Adoption of advanced diagnosis and treatment also plays an important role in the growth of this market.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/4123The global market of seasonal affective disorder was around USD 521.0 million in 2016 and is expected to reach USD 694.9 million by 2023 at a projected CAGR of 4.2%.Major Players in Seasonal Affective Disorder MarketSome of the key market players: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Henry Schein, Inc (US), Pfizer Inc. (US)Regional AnalysisThe global seasonal affective disorder market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.The Americas dominate this market, particularly North America due to increasing prevalence of this disorder in the region.
It is estimated that around 10 million Americans are affected by this disorder.
Growing awareness in South American population regarding this disorder is major driving force.Increasing cases of seasonal affective disorder in Europe is leading the market growth.
However, increasing healthcare expenditure, growing awareness, and increasing government support to improve life of patients drive this market.The Middle East & Africa region is expected to have the least growth during the forecast period due to lack of awareness about this disorder and limited access to healthcare facilities.SegmentationThe global seasonal affective disorder market is segmented on the basis of type, which includes fall and winter SAD, spring and summer SAD, and others.On the basis of diagnosis, the market is segmented into physical exam, lab tests, psychological evaluation, and others.
Lab tests is sub-segmented into complete blood count (CBC), thyroid blood tests, and others.
The study involved four major activities in estimating the current size of the HLA typing for the transplants market.
Exhaustive secondary research was conducted to collect information on the market and its different subsegments.The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.
Both top-down and bottom-up approaches were employed to estimate the total market size.
After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.Key Factors Driving Market Growth:The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the growing number of transplant procedures, and technological advancements in the field of transplant diagnostics.Revenue Growth Analysis:The HLA typing for the transplants market is expected to reach USD 968 million by 2025 from USD 656 million in 2019, at a CAGR of 6.7%Don’t miss out on business opportunities in HLA typing for transplants marketThe HLA typing for transplants market comprises several stakeholders such as original equipment manufacturers (OEMs), product distributors and channel partners, hospitals and transplant centers, emergency care units and trauma centers, diagnostic laboratories, contract manufacturers and third-party suppliers, research laboratories and academic institutes, clinical research organizations (CROs), government and non-governmental regulatory authorities, and market research and consulting firms.
Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.Browse in-depth TOC on “HLA Typing for Transplant Market”141 – Tables36 – Figures193 – PagesDownload PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96374742The HLA typing for the transplants market, by technology, is segmented into molecular and non-molecular assay technologies.
In 2019, the molecular assay technologies segment accounted for the largest share of the HLA typing for the transplants market.
